{"seq": 1, "variant": "control", "cmd": "pm quick --max 200 personalized dosimetry Lu-PSMA radioligand therapy -v", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "Searching PubMed: \"personalized dosimetry Lu-PSMA radioligand therapy\" (max 200)...\nFetching batch 1 (34 PMIDs)...\n", "elapsed_s": 1.489, "ts": 1771593273.027606}
{"seq": 2, "variant": "control", "cmd": "pm quick --max 200 personalized dosimetry Lu-PSMA radioligand therapy", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "", "elapsed_s": 1.882, "ts": 1771593282.6771667}
{"seq": 3, "variant": "control", "cmd": "pm filter --year 2023- --has-abstract", "exit_code": 0, "stdin_lines": 34, "stdout": "{\"pmid\": \"41506803\", \"title\": \"Nuclear Medicine and External Beam Radiation Therapy in Prostate Cancer: A Synergistic Approach.\", \"authors\": [\"Abdel-Wahab May\", \"Giammarile Francesco\"], \"journal\": \"Journal of nuclear medicine : official publication, Society of Nuclear Medicine\", \"year\": \"2026\", \"date\": \"2026-01-08\", \"abstract\": \"Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this combination leverages EBRT's precise targeting of visible tumors and RPT's ability to address microscopic or systemic disease. Clinical and preclinical evidence shows enhanced tumor control, improved pain relief, and improved quality of life with manageable toxicity. Advanced imaging-particularly prostate-specific membrane antigen (PSMA) PET-plays a pivotal role in precise disease mapping, patient selection, and therapeutic planning. PSMA-targeted RPT, including 177Lu-PSMA, expands the arsenal by delivering systemic radiation to PSMA-expressing cancer cells, with demonstrated overall survival benefits so far primarily in metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitors and taxane therapies. Although practical challenges such as access, regulation, and dosimetry remain, ongoing trials are exploring concurrent and sequential strategies, including \u03b1-emitter radioligands, aiming to improve survival. As evidence accumulates and logistical barriers are addressed, combined RPT and EBRT is poised to become a standard, personalized treatment paradigm in prostate cancer care.\", \"doi\": \"10.2967/jnumed.125.271268\"}\n{\"pmid\": \"41203980\", \"title\": \"Intra-arterial Hepatic 177Lu-PSMA-Radioligand Therapy in Liver-Dominant Metastatic Castration-Resistant Prostate Cancer: A Case Series.\", \"authors\": [\"Fakkert Ruben K\", \"Braat Arthur J A T\", \"de Keizer Bart\", \"Bruijnen Rutger C G\", \"Bruijnen Cheryl P\", \"Poot Alex J\", \"Smits Maarten L J\", \"Lam Marnix G E H\"], \"journal\": \"Cardiov", "stderr": "", "elapsed_s": 0.316, "ts": 1771593298.3040993}
